SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Conversion Notice and Total Voting Rights
9 February 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received a Conversion Notice on 5 February 2024 from Macquarie ("Macquarie") for £50,000 of Convertible Bonds from the £5.0 million convertible bond facility announced on 25 January 2024. The Company has drawn a total of £1,600,000 under the Facility.
This notice is for a pilot conversion to ensure smooth facilitation of the process.
SkinBioTherapeutics will issue 487,659 ordinary shares of £0.01 per share ("Ordinary Shares") at a conversion price of 10.25p per Ordinary Share.
Admission and Total Voting Rights
Application will be made for the 487,659 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 13 February 2024 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 190,850,600.
The above figure of 190,850,600 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
-Ends-
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
| For more information please contact: ?
About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain. The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps?, a food supplement to address the symptoms of mild to moderate psoriasis. The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.